EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The role of immunotherapy in the treatment of neuroblastoma

Naonori Kawakubo, Junnosuke Maniwa, Yoshiki Yamaguchi, Michiko Ueda, Yuko Hino, Amane Kamouchi, Kenta Ishimoto, Masahiro Fukuhara, Yoshiaki Takahashi, Yukihiro Toriigahara, Atsuhisa Fukuta, Koichiro Yoshimaru und 4 weitere

Surgery Today · 2026-09 · 56 (9) · 1723-1733

DOI: 10.1007/s00595-026-03327-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Surgery Today, online erschienen am 22.05.2026. Verfasst von Naonori Kawakubo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. kawakubo.naonori.061@m.kyushu-u.ac.jp. Hauptthemen laut MEDLINE: Neuroblastoma, Immunotherapy. Die Arbeit nennt 79 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroblastoma is the most common extracranial solid tumor in children. The prognosis for high-risk disease remains poor despite multimodal therapy, including chemotherapy, surgical resection, radiotherapy, and autologous stem-cell transplantation. Immunotherapy has improved outcomes remarkably, particularly using anti-GD2 monoclonal antibodies, which are now established as standard maintenance therapy. Combination regimens of cytokines and isotretinoin have enhanced survival, and chemo-immunotherapy has demonstrated superior response rates in relapsed/refractory settings. The aim of treatment with next-generation antibodies, such as humanized or Fc-engineered formats, is to reduce toxicity and improve efficacy. GD2-based vaccines and cellular therapies, including CAR-T cells, NK/NKT cell therapy, and bispecific antibody-armed T cells, have shown promising activity, particularly for minimal residual disease. However, challenges such as GD2 downregulation, an immunosuppressive tumor microenvironment, and manufacturing constraints persist. Future strategies may involve multimodal immunotherapy integrating antibodies, vaccines, and cellular platforms with precise patient selection and microenvironment modulation. Immunotherapy is reshaping neuroblastoma treatment, with the potential to achieve both deeper remission and long-term disease control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaImmunotherapyHumansGangliosidesCancer VaccinesCombined Modality TherapyAntibodies, MonoclonalTumor MicroenvironmentIsotretinoinCytokinesImmunotherapy, AdoptiveAntibodies, BispecificChildTreatment Outcome

Stichwörter der Autor:innen

Adoptive cell therapyAnti-GD2 antibodyImmunotherapyNeuroblastoma

Substanzen

Gangliosidesganglioside, GD2Cancer VaccinesAntibodies, MonoclonalIsotretinoinCytokinesAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. kawakubo.naonori.061@m.kyushu-u.ac.jp.
  • Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Zitieren

APA

Kawakubo, N., Maniwa, J., Yamaguchi, Y., Ueda, M., Hino, Y., Kamouchi, A., Ishimoto, K., Fukuhara, M., Takahashi, Y., Toriigahara, Y., Fukuta, A., Yoshimaru, K., Nagata, K., Miyata, J., Matsuura, T., & Tajiri, T. (2026). The role of immunotherapy in the treatment of neuroblastoma. Surgery Today, 56(9), 1723-1733. https://doi.org/10.1007/s00595-026-03327-8

Vancouver

Kawakubo N, Maniwa J, Yamaguchi Y, Ueda M, Hino Y, Kamouchi A, et al. The role of immunotherapy in the treatment of neuroblastoma. Surgery Today. 2026;56(9):1723-1733. doi:10.1007/s00595-026-03327-8

BibTeX
@article{Kawakubo2026,
  author = {Kawakubo, Naonori and Maniwa, Junnosuke and Yamaguchi, Yoshiki and Ueda, Michiko and Hino, Yuko and Kamouchi, Amane and Ishimoto, Kenta and Fukuhara, Masahiro and Takahashi, Yoshiaki and Toriigahara, Yukihiro and Fukuta, Atsuhisa and Yoshimaru, Koichiro and Nagata, Kouji and Miyata, Junko and Matsuura, Toshiharu and Tajiri, Tatsuro},
  title = {The role of immunotherapy in the treatment of neuroblastoma},
  journal = {Surgery Today},
  year = {2026},
  volume = {56},
  number = {9},
  pages = {1723--1733},
  doi = {10.1007/s00595-026-03327-8}
}
Kostenlos starten →